These observations suggest that targeting of STAT5 may be an interesting approach to block oncogenic signaling in MPN cells directly, but more potent and specific STAT5 inhibitors need to be developed to better inhibit MPN cell growth. The gene discussed is STAT5B; the disease is myeloproliferative disorder.